Press Releases Latest May 02, 2024 Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting Press Releases Year None202420232022202120202019201820172016201520142013 Feb 27, 2014 Theratechnologies announces financial results for fiscal year 2013 Feb 25, 2014 Theratechnologies to announce financial results for fiscal year 2013 Feb 14, 2014 Short Supply of EGRIFTA ® Announced Dec 13, 2013 Theratechnologies regains U.S. marketing rights to Egrifta Dec 03, 2013 Theratechnologies resumes shipment of tesamorelin to EMD Serono Nov 13, 2013 Jubilant HollisterStier Notifies Theratechnologies of Labour Disruption Nov 01, 2013 Health Canada Agrees to Reconsider Tesamorelin Oct 10, 2013 Theratechnologies Announces Financial Results for Third Quarter of 2013 Oct 03, 2013 Theratechnologies to Announce Third Quarter 2013 Financial Results Sep 18, 2013 EMD Serono notifies FDA of a Shortage of tesamorelin First page « Previous page ‹ … Page 29 Page 30 Page 31 Page 32 Page 33 Current page 34 Page 35 Page 36 Page 37 Next page › Last page » Displaying 331 - 340 of 361
May 02, 2024 Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting